Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition

被引：6

作者：

Van Poznak, Catherine ^{[1
]}

机构：

[1] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

来源：

BREAST CANCER RESEARCH | 2010年 / 12卷 / 03期

关键词：

ZOLEDRONIC ACID; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; FOLLOW-UP; PREVENTION; OSTEOPOROSIS; RISEDRONATE; TRIAL;

D O I：

10.1186/bcr2584

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The use of adjuvant aromatase inhibitors is associated with an increased risk of osteoporosis and fractures. The oral bisphosphonate, risedronate - dosed as the US Food and Drug Administration approved for the treatment or prevention of postmenopausal osteoporosis - appears to mitigate bone loss associated with 2 years of adjuvant anastrozole in women with early-stage breast cancer.

引用

页数：3

共 50 条

[21] A phase 3 study of the effect of denosumab therapy on bone mineral density in women receiving aromatase inhibitors for non metastatic breast cancer
Ellis, G.
Bone, H. G.
Chlebowski, R.
Paul, D.
Spadafora, S.
Smith, J.
Fan, M.
Jun, S.
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (03) : 585 - 586
[22] Clinical characteristics of bone fractures in breast cancer women receiving adjuvant aromatase inhibitors
Wojtacki, J.
Wiraszka, R.
Markowicz, A.
Piotrowska, M.
[J]. EJC SUPPLEMENTS, 2008, 6 (07): : 200 - 201
[23] Bisphosphonate use in women with breast cancer on aromatase inhibitor therapy
McGowan, A.
van der Kamp, S.
McKenna, M. J.
[J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2014, 183 : S463 - S463
[24] EFFECT OF ADJUVANT THERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH BREAST CANCER
Tsaaareli, M.
Giorgadze, E.
Khachidze, N.
Sharilcadze, N.
Dolidze, N.
Sulikashvili, T.
Jeiranashvili, N.
[J]. OSTEOPOROSIS INTERNATIONAL, 2014, 25 : S268 - S269
[25] Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy
Michael Dieckmeyer
Stefan Ruschke
Alexander Rohrmeier
Jan Syväri
Ingo Einspieler
Vanadin Seifert-Klauss
Monika Schmidmayr
Stephan Metz
Jan S. Kirschke
Ernst J. Rummeny
Claus Zimmer
Dimitrios C. Karampinos
Thomas Baum
[J]. BMC Musculoskeletal Disorders, 20
[26] Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy
Dieckmeyer, Michael
Ruschke, Stefan
Rohrmeier, Alexander
Syvaeri, Jan
Einspieler, Ingo
Seifert-Klauss, Vanadin
Schmidmayr, Monika
Metz, Stephan
Kirschke, Jan S.
Rummeny, Ernst J.
Zimmer, Claus
Karampinos, Dimitrios C.
Baum, Thomas
[J]. BMC MUSCULOSKELETAL DISORDERS, 2019, 20 (01)
[27] Bone Mineral Density (BMD) Changes at 1 Year in Postmenopausal Women Who Are Not Receiving Adjuvant Endocrine Therapy for Breast Cancer (BCA)
Van Poznak, C.
Morris, P. G.
D'Andrea, G.
Schott, A.
Griggs, J.
Fornier, M.
Smerage, J.
Henry, N. L.
Hurria, A.
Drullinsky, P.
Mills, N.
Hayes, D. F.
Hudis, C.
[J]. CANCER RESEARCH, 2009, 69 (24) : 559S - 559S
[28] Changes in bone mineral density with adjuvant aromatase inhibitor treatment and breast cancer recurrence.
Martin, Hilary
Redfern, Andrew D.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[29] Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study
Georgiana K. Ellis
Henry G. Bone
Rowan Chlebowski
Devchand Paul
Silvana Spadafora
Michelle Fan
Dennis Kim
[J]. Breast Cancer Research and Treatment, 2009, 118 : 81 - 87
[30] Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study
Ellis, Georgiana K.
Bone, Henry G.
Chlebowski, Rowan
Paul, Devchand
Spadafora, Silvana
Fan, Michelle
Kim, Dennis
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2009, 118 (01) : 81 - 87

← 1 2 3 4 5 →